Dulaglutide and long-acting insulin combo bests intensive insulin therapy for blood sugar control
Japan: A recent study from Japan found that a combination of dulaglutide and long-acting insulin ensued better glycemic control for 24 weeks than intensive insulin therapy alone. Fluctuations in blood glucose levels reduced and the number of self-injections needed has also decreased. The study results were published in the journal Diabetology International.
Diabetes is a global pandemic causing increased mortality and morbidity. Multiple drugs are used in the management of diabetes along with insulin therapy. Researchers from Japan conducted a study to evaluate the long-term effects of combination therapy of dulaglutide and long-acting insulin, on glycemic control in patients with type 2 diabetes.
A retrospective observational study was carried out on 20 patients with type 2 diabetes who underwent blood glucose management with intensive insulin therapy for a short duration. After this phase patients were changed from intensive insulin therapy to combination therapy comprising dulaglutide and long-acting insulin. Regular monitoring of hemoglobin A1c was done before and 4, 12, and 24 weeks after starting combination therapy. Glucose monitoring was also carried out continuously before and 1 and 24 weeks after starting combination therapy.
Key findings of the study:
- There was a significant reduction in the hemoglobin A1c levels after 4, 12, and 24 weeks of combination therapy.
- A significant decrease in glycemic variability (% coefficient of variation) was seen after 1 and 24 weeks of combination therapy.
- There was a significant improvement in the percentage of readings and time > 250 mg/dL at 24 weeks.
Thus, better blood glucose control was obtained with combination therapy of dulaglutide and long-acting insulin than with intensive insulin therapy.
Further reading: Ito, K., Satoh, S., Kondo, Y. et al. Effect of dulaglutide and long-acting insulin combination therapy in patients with type 2 diabetes: a retrospective observational study. Diabetol Int 14, 51–57 (2023). https://doi.org/10.1007/s13340-022-00592-z
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.